Navigation Links
Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
Date:2/28/2008

Nordic Biotech II K/S and MPM BioVentures close on additional $6 million

investment on top of $75 million previous investment

AMSTERDAM, Netherlands and ALAMEDA, Calif., Feb. 28 /PRNewswire/ -- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti- inflammatory therapies for treating respiratory diseases, completed a financing of 6 million USD led by new Investor Nordic Biotech II K/S and with participation by MPM BioVentures. Since its founding in 1997, Arriva has now raised a total of 81 million USD.

"Key financing from Nordic Biotech II KS and from our earlier lead investor, MPM Capital, allows us to continue the development of recombinant alpha-one antitrypsin for hereditary emphysema," said Sue Preston, CEO, Arriva Pharmaceuticals. "With a committed, experienced management team, we are now focused on the clinical development of our lead and pipeline products."

"We are investing in the clear value we see in Arriva's late-stage inhaled protein rAAT, a replacement product for the treatment of hereditary emphysema," said Florian Schonharting, partner of Nordic Biotech. "Our goal with Arriva is to provide financing and through board participation, help the company become a recognized, fully integrated biotech concern," added Christian Hansen, partner of Nordic Biotech.

"MPM has been a supporter of Arriva and the company's mission since 2002," said Ansbert Gadicke, General Partner, MPM Capital. "We continue to believe that there is significant potential in the company's respiratory product pipeline and are involved in this financing because we anticipate that Arriva will successfully capitalize on its IP and other assets."

About Arriva:

Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, chronic obstructive pulmonary disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva Pharmaceuticals BV, is headquartered in Amsterdam, the Netherlands, and its majority-owned subsidiary, Arriva Pharmaceuticals, Inc., is located in Alameda, California. For additional information please visit: http://www.arrivapharm.com

About Nordic Biotech:

Nordic Biotech is a global operating special situations fund family, with about 200 million USD under management. Primary focus is pharmaceutical development companies with late stage clinical programs. Nordic Biotech is based primarily in Copenhagen, Denmark with a presence in Boston and San Francisco. For more information, please visit http://www.NordicBiotech.com.

About MPM:

MPM Capital L.P. is a global investment management firm focused solely on life sciences investing. One of the largest investment management firms dedicated to the life sciences sector, MPM Capital has offices in Boston, San Francisco and New York City. MPM's portfolio ranges from start-ups to large capitalization public companies, with a primary focus on biopharmaceutical and medical device companies nearing commercialization of products or those companies that already offer product-driven opportunities. The firm manages over $2.5 billion in assets through the MPM BioVentures Family of venture capital funds and the MPM BioEquities public market fund. More information on MPM can be found at http://www.MPMCapital.com.


'/>"/>
SOURCE Arriva Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... , Dec. 8, 2016 Allergy Diagnostics ... products and tests that are used to determine ... peanuts, milk, or drugs etc. in the samples ... the immune system. The report on global allergy ... of the market. The report consists of an ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of the ... ... report analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. The report ... Japan , Europe , Asia-Pacific ... Annual estimates and forecasts are provided for the period 2015 through 2022. Also, ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, ... workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for ... . , According to the study, medical payments per claim in California decreased 4 ...
(Date:12/8/2016)... Little Rock, AR (PRWEB) , ... December 08, ... ... firm providing insurance and financial planning services from offices headquartered in Little Rock, ... Community Food Pantry. , According to the National Foundation to End Senior Hunger, ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Coppin Insurance ... owners and families in and around the Cape Coral area, is embarking on a ... Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest Florida ...
(Date:12/7/2016)... PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... trials with the announcement that it is one of the early adopters completing EU-U.S. ... Shield Framework is designed to provide companies on both sides of the Atlantic with ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
Breaking Medicine News(10 mins):